SHRUTI SHANKAR MD
Prescription History 1376006015
Internal Medicine - Pulmonary Disease in New Haven, CT
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SHRUTI SHANKAR MD, an active Pulmonary Disease specialist practicing in New Haven, CT. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 45 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 19 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other CT PrescribersVs. CT Avg |
|---|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $878.35▼ below CT avg | ▼ Less than typical |
About Trelegy Ellipta: This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. In 2024, this provider wrote 19 Medicare prescriptions for Trelegy Ellipta, about a quarter of the volume of the typical Connecticut prescriber of this medication (76.7). Medicare paid an average of $878.35 per fill, versus $898.80 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 26 30-Day Fills standardized to 30-day supplies 780 Days of Medication total across all patients in 2024 | |||
| Breo ElliptaFluticasone/Vilanterol | 14 | $400.27▼ below CT avg | ▼ Less than typical |
About Breo Ellipta: This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). Show more ▾ This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. In 2024, this provider wrote 14 Medicare prescriptions for Breo Ellipta, about a third of the volume of the typical Connecticut prescriber of this medication (41.3). Medicare paid an average of $400.27 per fill, versus $536.71 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 14 30-Day Fills standardized to 30-day supplies 420 Days of Medication total across all patients in 2024 | |||
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $20.82▼ below CT avg | ▼ Less than typical |
About Albuterol Sulfate Hfa: Albuterol (also known as salbutamol) is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). Show more ▾ It is also used to prevent asthma brought on by exercise. It is a quick-relief drug. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. In 2024, this provider wrote 12 Medicare prescriptions for Albuterol Sulfate Hfa, about 19% of the volume of the typical Connecticut prescriber of this medication (62.2). Medicare paid an average of $20.82 per fill, versus $23.90 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 12 30-Day Fills standardized to 30-day supplies 222 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for SHRUTI SHANKAR MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Pulmonary Disease prescribing approach at this New Haven, CT practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among CT prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
